Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT06746688 |
Title | The Trial is a First-in-human, Phase I, Open-label, Dose-escalating Trial to Assess the Safety and Tolerability of ES2B-C001 Combined With Montanide or Without Montanide, in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Metastatic Breast Cancer |
Recruitment | Recruiting |
Gender | both |
Phase | Phase I |
Variant Requirements | No |
Sponsors | ExpreS2ion Biotechnologies |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | AUT |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
Medical University Of Vienna | RECRUITING | Vienna | 1090 | Austria | Details |